This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients (SATIN)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: June 12, 2007
Last updated: June 27, 2011
Last verified: June 2011

The primary objective of this study is to assess the pathological Complete Response (pCR) rate by treatment arm (according to Chevallier criteria).

The secondary objectives are:

  • to assess in each treatment arm the clinical Response Rate (RR), the rate of breast conservation, the Progression-Free Survival (PFS), the Overall Survival (OS), the safety and tolerability profile, the pathological Complete Response rate (pCR) according to NSABP and Sataloff criteria,
  • to rank docetaxel and larotaxel alone in Her2 -ve patients, or combined with trastuzumab in Her2 +ve patients, according to the pCR rate.

Condition Intervention Phase
Breast Neoplasms Drug: larotaxel (XRP9881) Drug: docetaxel Drug: trastuzumab Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery. [ Time Frame: treatment period ]

Secondary Outcome Measures:
  • Clinical Response Rate, Rate of breast conservation, Progression-Free Survival, Overall Survival, pathological response according to NSABP and Sataloff criteria for patients who underwent surgery [ Time Frame: treatment period ]
  • Safety and tolerability profile [ Time Frame: treatment period ]

Enrollment: 330
Study Start Date: June 2007
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A1
Cohort 1: Her2-ve breast cancer
Drug: larotaxel (XRP9881)
intravenous administration
Active Comparator: Arm B1
Cohort 1: Her2-ve breast cancer
Drug: docetaxel
intravenous administration
Experimental: Arm A2
Cohort 2: Her2+ve breast cancer
Drug: larotaxel (XRP9881)
intravenous administration
Drug: trastuzumab
intravenous administration
Active Comparator: Arm B2
Cohort 2: Her2+ve breast cancer
Drug: docetaxel
intravenous administration
Drug: trastuzumab
intravenous administration


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven invasive breast adenocarcinoma
  • Localized breast cancer: stage II and III
  • Tumors clinically palpable and ineligible for breast conservative surgery: unifocal tumor with diameter ≥ 3cm (clinical examination) or central unifocal tumor, or whose characteristics make pre-operative chemotherapy mandatory due to high risk factors (i.e. ipsilateral lymph nodes involvement, rapid growth rate)
  • After 30 June 2008, known status for Her2neu by immunohistochemistry (IHC) or by fluorescent in situ hybridization (FISH)

Exclusion Criteria:

  • Bilateral and inflammatory breast cancer
  • Abnormal Left Ventricular Ejection Fraction
  • Distant metastases or locoregional relapse
  • Inadequate organ functions

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00485979

Sanofi-Aventis Administrative Office
Diegem, Belgium
Sanofi-Aventis Administrative Office
Sao Paulo, Brazil
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Warszawa, Poland
Sanofi-Aventis Administrative Office
Megrine, Tunisia
United Kingdom
Sanofi-Aventis Administrative Office
Guildford, United Kingdom
Sanofi-Aventis Administrative Office
Montevideo, Uruguay
Sponsors and Collaborators
Principal Investigator: Michel Marty, MD Centre for Therapeutic Innovations in Oncology and Haematology / Saint Louis University Hospital
  More Information

Responsible Party: Trial Transparency Team, sanofi-aventis Identifier: NCT00485979     History of Changes
Other Study ID Numbers: EFC10073
EudraCT 2006-006473-24
Study First Received: June 12, 2007
Last Updated: June 27, 2011

Keywords provided by Sanofi:
Breast Cancer
Neoadjuvant therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on August 18, 2017